Eligibility Cannot be Raised in IPR Appeal
Neptune Generics v. Eli Lilly (Fed. Cir. 2019) Mylan Labs v. Eli Lilly (Fed. Cir. 2019) This appeal combines twelve different inter partes review (IPR) proceedings. In each case, the PTAB Board sided with the patentee — holding that the claims of Lilly’s U.S. Patent 7,772,209 were not proven invalid. On appeal, the Federal Circuit has … Continue reading Eligibility Cannot be Raised in IPR Appeal
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed